Try arivis for free

30-day free trial offers a number of benefits.

Sahlgrenska Science Park

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

ZEISS Quality Innovation Days: April 15 – 19, 2024

Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

Mastering Urine Microscopy: Techniques for Accurate Disease Detection

Live Webinar on September 25, 2024.

HAB Nicolai Johannsen

AI automates testing of implant coatings

The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.

SMC Corporation Appoints Bianca Brunell as New General Manager for the Nordic and Baltic Countries

SMC Corporation is pleased to announce the appointment of Bianca Brunell as the new General Manager for SMC’s Nordic and Baltic countries, effective June 1, 2024.

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

”Information security must become part of the Swedish life science strategy”

Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.

AstraZeneca moves to brewery quarters in central Copenhagen

AstraZeneca in Denmark is moving its business into central Copenhagen and the old brewery quarters in Carlsberg Byen.

List: The coolest names in biotech

Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuti...

”We need compatibility“

Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on ef...

Learn from Speakers from Leading MedTech Companies

Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.

Here are the pharmaceutical companies best prepared for AI

How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.

Danish obesity success causes recruitment problems in southern Sweden

The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.

Innovative start-up helps doctors, scientists and industry balance coagulation risks

For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thro...

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Recipharm divests five Swedish plants

Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity compa...

Nocebo – the evil twin that makes you feel worse

The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...

A new giant among our microscopes

Two technologies in one machine.

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.